Avalyn Pharma outlined plans for an IPO targeting proceeds to accelerate clinical development of inhaled respiratory therapies. The company set an approximately $182 million IPO goal, aiming to fund advancement of its inhaled platform into later-stage studies for respiratory diseases. The financing plan arrives as inhaled drug delivery remains an active area for differentiation, particularly for expanding label opportunities in pulmonary conditions. For investors, the IPO target size and clinical runway indicate Avalyn is positioning for scale-up across advanced trial stages rather than staying in early discovery.